BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 16198399)

  • 1. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
    Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
    Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
    de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
    Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
    Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
    Oda Y; Ohishi Y; Basaki Y; Kobayashi H; Hirakawa T; Wake N; Ono M; Nishio K; Kuwano M; Tsuneyoshi M
    Cancer Sci; 2007 Jul; 98(7):1020-6. PubMed ID: 17459055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
    Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
    Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis].
    Han XY; Chen Y; Hou MM; Zhang J; Yang KX; Chen YY; Qie MR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):619-22, 634. PubMed ID: 18798508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias--correlation to the expression of multidrug resistance proteins.
    Fichtner I; Paal K; Borgmann A; Badiali L; Wurm R; Henze G
    Anticancer Res; 2003; 23(3B):2657-64. PubMed ID: 12894554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of multidrug resistance-related markers in primary neuroblastoma.
    Lu QJ; Dong F; Zhang JH; Li XH; Ma Y; Jiang WG
    Chin Med J (Engl); 2004 Sep; 117(9):1358-63. PubMed ID: 15377429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
    Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
    Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
    J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.